Welcome to our dedicated page for Biolife Solutions news (Ticker: BLFS), a resource for investors and traders seeking the latest updates and insights on Biolife Solutions stock.
BioLife Solutions, Inc. (NASDAQ: BLFS) is a developer and supplier of cell processing tools and services and bioproduction products and services for the cell and gene therapy (CGT) and broader biopharma markets. News about BLFS often centers on how its biopreservation media, CellSeal vials, hPL products, and related cell processing tools are used in clinical trials and commercial CGT therapies, as well as on portfolio changes and strategic transactions.
Investors and industry followers can use this page to track BioLife’s announcements on quarterly and annual financial results, including updates on Cell Processing revenue and the performance of its biopreservation media franchise. The company regularly reports on the contribution of customers with approved therapies, the extent of clinical trial adoption in the United States, and its use of GAAP and non-GAAP measures such as adjusted gross margin and adjusted EBITDA.
BioLife’s news flow also includes updates on portfolio streamlining and strategic moves, such as the divestiture of its evo cold chain logistics subsidiary and earlier sales of Global Cooling, SciSafe, and Custom Biogenic Systems, as well as acquisitions and investments like the PanTHERA CryoSolutions IRI cryopreservation technology and the strategic investment in Pluristyx. These items illustrate how the company is focusing on its core cell processing business while adding scientific capabilities and adjacencies.
In addition, BioLife issues press releases on corporate developments such as the opening of the Aby J. Mathew Center for Biopreservation Excellence in Bothell, Washington, and participation in healthcare and small- and mid-cap investor conferences. For readers following the CGT supply chain, this news page provides a centralized view of BioLife’s operational updates, clinical adoption metrics, strategic transactions, and investor communications over time.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
BioLife Solutions reported a record full year revenue of $161.8 million for 2022, marking a 36% increase from 2021, with biopreservation media revenue growing by 45%. Q4 2022 revenue reached $44.3 million, up 19% year-on-year. Adjusted EBITDA for the year was $3.6 million, and for Q4, it was $1.7 million. The company anticipates 2023 revenue between $188 million and $202 million, reflecting growth rates of 16% to 25%. CEO Mike Rice emphasized continued demand for their products in the growing cell and gene therapy markets, with expected revenue growth largely driven by cell processing platforms and storage services.
BioLife Solutions (NASDAQ: BLFS) has addressed its banking relationship with Silicon Valley Bank (SVB) amid recent concerns. The company states there is no immediate risk to its operations, with deposit accounts at SVB below $1 million, well within FDIC insurance limits. BioLife also mentions that its credit facility with SVB remains under assessment but anticipates no short-term borrowing needs. Furthermore, various other institutions manage their third-party investments, mitigating potential liquidity issues linked to SVB.
BioLife Solutions (NASDAQ: BLFS) will release its fourth quarter and full year 2022 financial results after market close on March 16, 2023. The company will also host a conference call at 4:30 PM ET to discuss these results and provide a general business update. Investors can access the call via BioLife's Investor Relations page or by dialing in. The results are critical as they will reflect BioLife's performance in the rapidly evolving cell and gene therapy market, where it supplies bioproduction tools and services. The conference call will also include insights into the company's future outlook.
BioLife Solutions (NASDAQ: BLFS) has launched Ultraguard, a groundbreaking non-toxic and non-flammable -70°C phase change material (PCM) designed for ultra-low temperature (ULT) protection. This innovative product serves two main applications: maintaining temperature during power outages in ULT freezers and providing a safer, more economical alternative to dry ice for benchtop storage of biologic materials. Ultraguard addresses storage challenges posed by extreme weather and electrical grid issues, enhancing operational reliability for clients. Beta tests with significant customers, including major logistics providers, confirm its effectiveness.
BioLife Solutions, a leader in bioproduction products for cell and gene therapy, has announced its 2023 Analyst Day scheduled for March 23, 2023, at SciSafe Biorepository in Billerica, MA. The event will feature discussions on product updates, portfolio progress, and financial performance, with in-person attendance by invitation only. Virtual participation will be available starting March 1, 2023. Additionally, BioLife will partake in several investor conferences, including the Cowen Annual Health Care Conference on March 7 and the Oppenheimer Healthcare Conference on March 14. For further information, visit BioLife Solutions.